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Current knowledge on the regulation of mammalian
pigmentation at the genetic and biochemical level, and
constituents that participate in melanosomal organiza-
tion, is summarized. Approximately 25% of the more
than 80 genes known to regulate pigmentation in
mammals have been cloned and characterized to date.
Almost half of those encode proteins that localize,
either specifically or nonspecifically, to melanosomes;
mutations in those genes generally lead to phenotypic
changes in pigmentation as well as in other pleiotropic
Melanins are unique pigmented biopolymers synthe-sized by specialized cells known as melanocytes,dendritic cells that exist as relatively minor popula-tions in the skin, hair, eyes and other locations (asreviewed by Spritz and Hearing, 1994; King et al,
1995, 1997; Hearing, 1997). Melanins are produced and deposited
within discrete membrane-bound organelles known as melanosomes,
and visible pigmentation depends on the size, number, shape and
distribution of those melanosomes as well on the chemical nature of
the melanins deposited within them. In the skin, melanocytes residing
at the dermal–epidermal border propel melanosomes they produce into
their dendrites as they mature and then transfer them to surrounding
proliferating keratinocytes. Movement of these keratinocytes towards
the surface of the skin, and the distribution of their ingested melano-
somes, eventually yields visible skin color. Similarly, melanocytes
responsible for hair pigmentation reside deep within hair bulbs in the
dermis. Again, they are a relatively minor cell population that produce
melanosomes and transfer them to the growing hair shaft; the processed
and distributed melanosomes in the emerging hair shaft give it color.
Melanin has a number of important and distinct functions, ranging
from its role in the determination of phenotypic appearance (Ortonne
and Prota, 1993), to protective coloration (Jackson, 1991, 1993), to
balance and auditory processing (Creel et al, 1983, 1990), to absorption
of toxic drugs and chemicals (Lindquist, 1973; Larsson, 1995), and to
neurologic development during embryogenesis (Proctor, 1976; King
et al, 1985; Creel et al, 1986). With respect to the topic of this
Symposium, however, melanin’s most relevant function is protection
from ultraviolet light, and thus prevention of UV-induced photodam-
age, photoaging, and photocarcinogenesis.
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changes. The expression and function of these proteins
not only affects phenotypic appearance, but also the
properties of melanins, especially their photoprotective
characteristics. Because many of those melanosomal
proteins also serve as melanoma-specific targets, regula-
tion of their expression has dramatic implications for
immune targeting of malignant melanoma. Key words:
melanin/melanoma/photoabsorption/pigmentation. Journal of
Investigative Dermatology Symposium Proceedings 4:24–28,
1999
It should be obvious from the comments above that many different
types of cells interact to determine pigmented phenotype, and con-
sequently that regulation of melanogenesis is a complex process. In fact,
the number of genes involved in regulating mammalian pigmentation is
quite large, and at least 80 genetic loci regulate melanogenesis either
directly or indirectly. At this moment, 21 of those genes have been
cloned, and in most instances, analogous genes have been cloned and
at least partially characterized functionally in mice and in humans. So
far, virtually all of them have comparable functions in both species,
and in many instances, mutations in those genes have been shown to
be associated with different human pigmentary diseases, including
various forms of ocular and oculocutaneous albinism (OCA), pie-
baldism, Hirschsprung’s disease, and Waardenberg’s syndrome.
Genes that regulate mammalian pigmentation act at the tissue, the
cellular, the subcellular, and/or the environmental level. To get
appropriate pigmentation and patterning, melanoblasts must originate
in the neural crest during embryologic development, and they must
be given appropriate signals, first to mature and then to migrate in
distinct fashions throughout the organism. Obviously, once melanoblasts
have arrived at their intended destinations, they must receive the
appropriate signal(s) to stop migrating and to then differentiate into
melanocytes. Mature melanocytes must of course then be able to
respond to environmental signals, and they must be competent to
produce melanosomes and the melanins within them, and to then
transfer them to keratinocytes. It is not surprising then that there are
a relatively large number of genes involved in the regulation of these
diverse processes, and mutations in genes important to each of those
steps have been identified that interfere with normal pigmentation.
Inherited mutations of those genes are responsible for many of the
known clinical pigmentary abnormalities.
Time and space does not permit a full discussion of these genes and
their functions, but briefly, pigment genes that function at the tissue
level affect the eventual distribution of melanocytes in tissues; they
typically encode transcription factors or growth factors (or their
receptors) important to melanoblast function. Genes cloned to date
that fall into this category include the splotch, dom, white-spotting, steel,
and patch loci. A more thorough discussion and references to original
articles of the pigment related genes can be found in the following
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Table I. Genes encoding melanosome proteins/associated diseasesa
Mouse locus Human disease Encoded protein
Genes encoding melanosome specific proteins
albino OCA1 tyrosinase – melanogenic enzyme
brown OCA3 TRP1/Tyrp1 – melanogenic enzyme
MART1 Vogt-Koyanagi–Harada syndrome MART1 – melanosome membrane protein
OA1 ocular albinism – type 1 OA1 – melanosome membrane protein
pinkeyed-dilution OCA2 p protein – membrane transporter?
silver hair silvering? Pmel17 – melanosome matrix protein
slaty OCA4? TRP2/Dct – melanogenic enzyme
Genes encoding lysosome/platelet/melanosome specific proteins
ashen unknown RAB-related GTPase
beige Chediak–Higashi syndrome LYST lysosomal membrane protein
dilute Griscelli disease MYH12 myosin type V
mocha unknown δ subunit AP-3 complex
mottled Menkes disease ATP7 A copper transporter
pale ear Hermansky–Pudlak syndrome HPS lysosomal membrane protein
pallid platelet storage pool disease protein 4.2 pallidin
pearl unknown β subunit AP-3 complex
acf. Spritz and Hearing (1994), King et al (1997), and Hearing (1998) for full references.
Figure 1. The reaction cascade of the melanogenic pathway. cf. Hearing, 1998 for complete references.
review articles (Bennett, 1991, 1993; Spritz and Hearing, 1994; King
et al, 1995, 1997; Hearing, 1998). It must be borne in mind, however,
that the ultimate distribution of melanin particles in the upper layers
of the skin are critically important to the efficacy of photoprotection
of that tissue. Although the various types of melanins as discussed
below are chemically determined and synthesized in melanocytes, it is
their transfer and processing in keratinocytes en route to the surface of
the skin that ultimately provides effective photoprotection from UV
light (Kaidbey et al, 1979; Prota, 1994; Jimbow et al, 1995; Kobayashi
et al, 1998).
Pigment genes that function at the cellular level include genes that
affect whether melanocytes survive and/or proliferate once in place.
Several genes have now been cloned that act at this level, either in
events that determine the initial differentiation of melanoblasts to
melanocytes, or in their subsequent survival and proliferation. Typically
such genes include those that encode factors (e.g., endothelin or steel
factor) that stimulate melanocyte differentiation or survival, such as the
microphthalmia, piebald lethal, and lethal spotting loci. Other genes in this
category encode proteins required for pigmentation, but not necessarily
restricted to pigmentation, e.g., those that encode subcellular organelle
membrane proteins (i.e., proteins functional in organelles of the
melanosome/lysosome/platelet lineage). Genes that fall into this cat-
egory include those at the ashen, beige, dilute, mocha, mottled, pale ear,
pallid, and pearl loci. Mutations in these genes typically lead to abnormal
pigmentation because of the dysfunctional melanosomes produced, but
also lead to pleiotropic effects due to malfunction of other related
organelles (such as lysosomes and/or platelets) that also require those
gene products for their function.
Pigment genes that are expressed specifically in melanocytes fall into
the group that function at the subcellular level; they are genes that
encode typically melanosome-specific proteins – melanosomes being
the specific organelle produced only by melanocytes. Seven genes that
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Figure 2. Properties of biologic melanins in
ultraviolet photoabsorption. →, no change or no
function; ↑, significant increase in function; ↑↑, very
dramatic increase in function; ↓, significant decrease in
function; ↓↓, very dramatic decrease in function.
function at this level have been cloned so far, and they encode
melanosomal proteins that are functional enzymatically or structurally.
These are discussed in more detail below, but include those at the
albino, brown, MART1, OA1, pinkeyed-dilution, slaty, and silver loci.
Genes that encode proteins found in melanosomes (either specifically
or nonspecifically) are listed in Table I, along with their putative
functions and associated pigmentary diseases.
In the final group are genes that regulate melanocyte function as
environmental factors. These include the extension locus (which encodes
the MSH receptor), the agouti locus (which encodes the agouti signal
protein), and the piebald lethal locus (which encodes the endothelin-1
receptor). All of these play important roles in modulating melanocyte
function and thereby affecting pigment production. Of course, gene
encoding the ligands for those receptors should also be included on
this list; however, this is by necessity a very incomplete list at this time
because a wide variety of physiologic factors are known to affect
melanocyte proliferation and/or differentiation and will surely be added
in the future. Included among such factors that are currently not listed
are a number of cytokines, lymphokines, prostaglandins, vitamins, and
growth factors known to modulate melanocyte function (reviewed in
Hearing, 1998). Many of those factors are produced by melanocytes
themselves (in an autocrine fashion), or by other cells in the epidermis
(such as keratinocytes or Langerhans cells) and/or in the dermis (such
as inflammatory cells, endothelial cells, or mast cells). Some of those
signals regulate the type of melanin that is produced and/or how much
of it is produced, whereas others affect the growth, dendricity,
migration, or survival of melanocytes and thereby exert their effects
on pigmentation. It is obvious that the melanocyte is in an extremely
interactive environment and responds to signals coming from virtually
every source and direction.
The sum of those factors regulate the amounts and types of melanins
produced by melanocytes, although the exact chemical structures and
properties of different melanins are not yet completely known. Tyrosine
is the physiologic substrate required for melanin production and the
initial catalytic function of tyrosinase, i.e., the hydroxylation of tyrosine
to DOPA, is the essential and rate-limiting activity for melanin
formation. Once produced, DOPA can auto-oxidize and cyclize
spontaneously to produce 5,6-dihydroxyindole (DHI) melanin (Fig 1);
however, tyrosinase is not the only melanogenic enzyme involved in
the pathway and there are at least three other melanosomal proteins
that in part determine melanin production. The first of these is
DOPAchrome tautomerase, also known as tyrosinase related protein 2
(TRP2 or Dct); TRP2 functions specifically to tautomerize DOPA-
chrome to 5,6-dihydroxyindole-2-carboxylic acid (DHICA). DHICA
is a melanogenic intermediate that still contains the carboxylic acid
group, which is spontaneously lost in the absence of TRP2 catalytic
activity upon which DHI is produced. Melanins generated in vitro from
DHICA are brown in color, poorly soluble, and of intermediate
molecular weight, whereas those generated from DHI derivatives are
black, completely insoluble, and of high molecular weight. Yet another
melanogenic enzyme, known as tyrosinase-related protein 1 (TRP1 or
Tyrp1), functions as a DHICA oxidase, and promotes further oxidation
and polymerization of DHICA-melanins. The product of the silver
locus, known as the silver protein (or Pmel17), also functions in
melanogenesis as a polymerase, possibly by serving as a solid-phase
substrate upon which melanin polymerization proceeds. The DHI-
and DHICA-melanins are not only distinctly different visibly, but have
other important differences in their properties as well, as for example
in their photoprotective and cytotoxic properties (reviewed in Prota,
1992). The DHI- and DHICA-melanins produced downstream of
DOPAchrome are termed eumelanins.
The other major diversion in the melanogenic pathway occurs
upstream in the pathway immediately following the production of
DOPAquinone from DOPA. It is not yet known how this switch to
produce pheomelanin is regulated, but if a sulfhydryl donor, probably
cysteine (Potterf et al, 1998), is available when DOPAquinone is
generated, the latter will be stoichiometrically converted to cysteinyl-
DOPA. Once this sulfur group has been incorporated into the melanin
polymer, further oxidation, cyclization, and polymerization leads to
the production of pheomelanin. Pheomelanins are yellowish-red in
color, quite soluble, and of very low molecular weight. Mammals with
yellow or bright red hair typically result from pheomelanin production,
whereas brownish or black hair results from the production of
eumelanins. It is important to realize that the melanocyte effectively
determines, depending on whether cysteinylDOPA, DHI, and/or
DHICA is made, which type of melanin is ultimately produced by
further oxidation and polymerization, and this in turn dramatically
affects the various physical properties of those melanins, including their
photoprotective function (Jimbow et al, 1995; Pathak, 1995; Hill
et al, 1997).
It is not yet completely clear how the switch to produce eu- or
pheo-melanins is effected, although in mice it has been known for
some time that interactions between MSH and ASP are critical to this
(reviewed in Barsh, 1995, 1996). Conditions under which there is
over-stimulation of MSH receptor function elicit eumelanin production
and a black phenotype, whereas conversely, conditions under which
function of the MSH receptor is abrogated or is overwhelmed by ASP
overexpression, result in the production of pheomelanin. Recent
studies (Valverde et al, 1995; Smith et al, 1998) have clearly shown
that MSH and ASP function similarly in humans as they do in mice,
although levels of response in human melanocytes may be muted
compared with lower mammals.
Melanosomes have been known for some time to consist of 30 or
more different proteins, some of them specific to this organelle, whereas
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Table II. Melanosomal-specific proteins that elicit immune responsesa
Disease (type of response) gp100/Pmel17 tyrosinase TRP1/gp75 TRP2/Dct MART-1 B700
melanoma (humoral) X X
melanoma (cellular) X X X X X
vitiligo (humoral) X X X X
Vogt-Koyanagi Harada (cellular) X
acf. Hearing (1996) and Sakai et al (1997b) for pertinent references.
others are shared with other subcellular components such as lysosomes
and platelets (Orlow, 1995). So far, genes encoding 15 such proteins
have been cloned; these include the four melanogenic enzymes
(tyrosinase, TRP1, TRP2, and silver) noted above. Three other
melanosome-specific membrane proteins have also been cloned,
encoded at the MART1, OA1, and pinkeyed-dilution loci; the functions
of those proteins are still under investigation. A summary of currently
cloned genes that encode melanosomal proteins (specific or nonspecific)
is shown in Table I.
Our laboratory has been studying the level(s) at which MSH and
ASP exert their dramatic effects on melanin production. If MSH is
used to stimulate pigmentation, tyrosinase expression is dramatically
increased but there is little or no change in TRP1, TRP2, or silver
expression or function. ASP, on the other hand, decreases almost all
melanogenic gene expression (Kobayashi et al, 1995; Sakai et al, 1997a).
We have found that these changes in gene expression are reflected at
the protein level as well, and consistent with those observations, the
catalytic functions of those enzymes are similarly affected, and the
melanin contents are dramatically affected. These results predict dra-
matic increases or decreases in visible melanin production by melano-
cytes responding to MSH or ASP, respectively, and that is indeed
found. How these transcriptional events are regulated has become an
interesting target of study and a recent report has demonstrated that
the responses are complex indeed, involving a number of transcription
factors and structural proteins within melanocytes (Furumura et al,
1998).
UV stimulation of melanogenesis is remarkably similar to that of
MSH treatment (Archambault et al, 1995; Gilchrest et al, 1996).
Following chronic UVB exposure, there are dramatic increases, not
only in the number and dendricity of melanocytes, but also in the
amount of melanin produced in those melanocytes and transported to
the surface of the skin. It has been proposed that the UV response
may be elicited via increases in MSH receptor expression and function
in melanocytes (Bolognia et al, 1994; Chakraborty et al, 1995).
Important questions remain about the implication(s) of making
different types of melanins (Fig 2). Production of the darker and
more polymerized DHI-melanins maximizes photoabsorption but also
increases cytotoxic effects (but with no apparent phototoxic effect)
(Jimbow et al, 1995; Schmitz et al, 1995). DHICA-melanins have
somewhat reduced photoabsorptive properties (and are not very
phototoxic), but have a dramatically decreased cytotoxicity towards
the cell (Hochstein and Cohen, 1963; Pawelek and Lerner, 1978;
Urabe et al, 1994). In contrast, pheomelanin provides little or no
photoabsorption and has a relatively high phototoxic content, but with
very low cytotoxicity (Chedekel and Zeise, 1988; Young, 1994;
Chedekel, 1995; Kollias, 1995). A complication is added when con-
sidering malignant melanoma, because many of these differentiation
proteins are targets of the immune system (Table II). Melanoma cells
whose pigment production is downregulated, or perhaps even worse,
switched to pheomelanin production, obviously have dramatically
downregulated expression of these potential antigens, and thus are
more obscure targets for the immune system (Soballe and Herlyn,
1994; Orlow et al, 1995; Meier et al, 1998). Because TRP2 is perhaps
the most widely expressed melanocyte-specific antigen by melanomas
of varying phenotype (Orlow et al, 1995, 1998; Reynolds et al, 1998),
a switch to DHI-melanins implies a decrease in TRP2 expression and
function and therefore further implies a decrease in immune-targeting
potential. Therefore in light of all these considerations, the optimum
type of melanin for melanocytes to be producing is probably derived
from DHICA; these DHICA-melanins would provide a good com-
promise between maximizing photoprotection while minimizing cyto-
toxicity, and imply that all melanosomal antigens are being expressed.
It is important to recognize the fact that the commitment to produce
one or another type of melanin has varied consequences to the
melanocyte and the skin in which it resides on many different levels.
In summary, mammalian pigmentation is a very complex process. It
is regulated at different levels by many distinct factors. The genes and
regulatory processes involved in melanin formation are now being
identified rapidly; about 25% of the known genes have already been
cloned and characterized, and this will probably increase to 50% or
60% over the next decade. Many of these gene products have been
shown to be involved in various clinical pigmentary diseases, and many
also play important roles in immune responses to malignant melanoma.
This is exciting and new information because we are now rapidly
achieving a better position to evaluate various clinical pigmentary
conditions, and potentially to help such patients.
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